

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <b>BAKER G LEONARD JR</b>  (Last) (First) (Middle) <b>755 PAGE MILL ROAD</b> <b>SUITE A-200</b>  (Street) <b>PALO ALTO CA 943041005</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>CORCEPT THERAPEUTICS INC [ CORT ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>04/19/2004</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/19/2004		C		207	A	(1)	207	D	
Common Stock	04/19/2004		C		3,369	A	(2)	3,576	D	
Common Stock	04/19/2004		C		201,863	A	(2)	205,439	D	
Common Stock	04/19/2004		C		110,544	A	(1)	110,544	I	By Ltd Partnership <sup>(3)</sup>
Common Stock	04/19/2004		C		77,322	A	(1)	187,866	I	By Ltd Partnership <sup>(3)</sup>
Common Stock	04/19/2004		C		12,392	A	(2)	200,258	I	By Ltd Partnership <sup>(3)</sup>
Common Stock	04/19/2004		C		56,516	A	(2)	256,774	I	By Ltd Partnership <sup>(3)</sup>
Common Stock	04/19/2004		C		8,019	A	(1)	8,019	I	By Ltd Partnership (SHAI) <sup>(4)</sup>
Common Stock	04/19/2004		C		1,228	A	(2)	9,247	I	By Ltd Partnership (SHAI) <sup>(4)</sup>
Common Stock	04/19/2004		C		5,775	A	(1)	15,022	I	By Ltd Partnership (SHAI) <sup>(4)</sup>
Common Stock	04/19/2004		C		7,400	A	(2)	22,422	I	By Ltd Partnership (SHAI) <sup>(4)</sup>
Common Stock	04/19/2004		C		20,304	A	(1)	20,304	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Common Stock	04/19/2004		C		3,109	A	(2)	23,413	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Common Stock	04/19/2004		C		14,619	A	(1)	38,032	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Common Stock	04/19/2004		C		18,736	A	(2)	56,768	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Common Stock	04/19/2004		C		791,586	A	(1)	791,586	I	By Ltd Partnership (SHV) <sup>(6)</sup>

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/19/2004		C		121,780	A	(2)	913,366	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Common Stock	04/19/2004		C		569,940	A	(1)	1,483,306	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Common Stock	04/19/2004		C		732,882	A	(2)	2,216,188	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Common Stock	04/19/2004		C		6,279	A	(1)	6,279	I	By Trust <sup>(7)</sup>
Common Stock	04/19/2004		C		4,521	A	(1)	10,800	I	By Trust <sup>(7)</sup>
Common Stock	04/19/2004		C		966	A	(2)	11,766	I	By Trust <sup>(7)</sup>
Common Stock	04/19/2004		C		5,812	A	(2)	17,578	I	By Trust <sup>(7)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			69	(8)	(9)	Common Stock	207	(1)	0	D	
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			36,848	(8)	(9)	Common Stock	110,544	(1)	0	I	By Ltd Partnership <sup>(3)</sup>
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			2,673	(8)	(9)	Common Stock	8,019	(1)	0	I	By Ltd Partnership (SHAD) <sup>(4)</sup>
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			6,768	(8)	(9)	Common Stock	20,304	(1)	0	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			263,862	(8)	(9)	Common Stock	791,586	(1)	0	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Series A Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			2,093	(8)	(9)	Common Stock	6,279	(1)	0	I	By Trust <sup>(7)</sup>
Series B Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			25,774	(8)	(9)	Common Stock	77,322	(1)	0	I	By Ltd Partnership <sup>(3)</sup>
Series B Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			1,925	(8)	(9)	Common Stock	5,775	(1)	0	I	By Ltd Partnership (SHAD) <sup>(4)</sup>
Series B Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			4,873	(8)	(9)	Common Stock	14,619	(1)	0	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Series B Preferred Stock	\$0.0000 <sup>(1)</sup>	04/19/2004		C			189,980	(8)	(9)	Common Stock	569,940	(1)	0	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			201,863	(8)	(9)	Common Stock	201,863	(2)	0	D	
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			56,516	(8)	(9)	Common Stock	56,516	(2)	0	I	By Ltd Partnership <sup>(3)</sup>
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			7,400	(8)	(9)	Common Stock	7,400	(2)	0	I	By Ltd Partnership (SHAD) <sup>(4)</sup>
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			18,736	(8)	(9)	Common Stock	18,736	(2)	0	I	By Ltd Partnership (SHQP) <sup>(5)</sup>
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			732,882	(8)	(9)	Common Stock	732,882	(2)	0	I	By Ltd Partnership (SHV) <sup>(6)</sup>
Series C Preferred Stock	\$0.0000 <sup>(2)</sup>	04/19/2004		C			5,812	(8)	(9)	Common Stock	5,812	(2)	0	I	By Trust <sup>(7)</sup>



POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby authorizes David E. Sweet, Robert Yin, Patricia Tom, David L. Anderson, Tench Coxe, James C. Gaither, Gregory P. Sands, James N. White, or William H. Younger, Jr. to execute for and on behalf of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Inc. ("the Company"), and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such a capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

In witness whereof, the undersigned has caused this Power of Attorney to be executed as of this 9th day of April, 2004.

/s/ G. Leonard Baker, Jr.